Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tryptamine Therapeutics ( (AU:ENP) ) has shared an update.
Entropy Neurodynamics has released documentation for its 2026 Extraordinary General Meeting, including a letter of access, notice of meeting and proxy form, signalling the next phase of shareholder engagement and corporate governance activity. The company is also encouraging investors to use the Automic Group portal to manage their holdings and switch to electronic communications, in a move that may streamline investor relations and reduce administrative overhead, while continuing to highlight both the therapeutic potential and managed risks associated with psilocin-based treatments under medical supervision.
The most recent analyst rating on (AU:ENP) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Tryptamine Therapeutics stock, see the AU:ENP Stock Forecast page.
More about Tryptamine Therapeutics
Entropy Neurodynamics Limited is a Melbourne-based, clinical-stage biotechnology company focused on developing proprietary psilocin formulations combined with psychotherapy for diseases with unmet medical needs. Its lead candidate, TRP-8803, is an intravenous psilocin formulation designed to address limitations of oral psilocybin, including onset time, control of psychedelic depth and duration, and overall treatment time, building on Phase 2a trials in binge eating disorder, irritable bowel syndrome and fibromyalgia.
Average Trading Volume: 2,214,598
Technical Sentiment Signal: Sell
Current Market Cap: A$50.03M
For detailed information about ENP stock, go to TipRanks’ Stock Analysis page.